BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment

Winter, Georg E., Mayer, Andreas, Buckley, Dennis L., Erb, Michael A., Roderick, Justine E., Vittori, Sarah, Reyes, Jaime M., di Iulio, Julia, Souza, Amanda, Ott, Christopher J., Roberts, Justin M., Zeid, Rhamy, Scott, Thomas G., Paulk, Joshiawa, Lachance, Kate, Olson, Calla M., Dastjerdi, Shiva, Bauer, Sophie, Lin, Charles Y., Gray, Nathanael S., Kelliher, Michelle A., Churchman, L. Stirling, Bradner, James E.·2017·Molecular Cell
DOI 10.1016/j.molcel.2017.06.004

Cited by (469)

Items 101–200 of 469

  1. The Histone Deacetylase SIRT6 Restrains Transcription Elongation via Promoter-Proximal Pausing
    Jean‐Pierre Etchegaray, Lei Zhong, Catherine Li, Telmo Henriques, Eileen F. Ablondi, Tomoyoshi Nakadai, Capucine Van Rechem, Christina M. Ferrer, Kenneth N. Ross, Jee-Eun Choi et al. · 2019 · Molecular Cell
  2. BRD4 in physiology and pathology: ‘‘BET’’ on its partners
    Yin Liang, Jieyi Tian, Tao Wu · 2021 · BioEssays
  3. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
    Warren C. Fiskus, Tianyu Cai, Courtney Denton Dinardo, Steven Mitchell Kornblau, Gautam M. Borthakur, Tapan Mahendra Kadia, Naveen Pemmaraju, Prithviraj Bose, Lucia Masárová, Kimal Rajapakshe et al. · 2019 · Blood Cancer Journal
  4. Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive Chemistry
    Roman C. Sarott, Inchul You, Yen-Der Li, Sean T. Toenjes, Katherine A. Donovan, Pooreum Seo, Martha Ordonez, Woong Sub Byun, Muhammad Murtaza Hassan, Franziska Wachter et al. · 2023 · Journal of the American Chemical Society
  5. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains
    Jinhua Wang, Tatiana Erazo, Fleur M. Ferguson, Dennis L. Buckley, Néstor Gómez, Pau Muñoz‐Guardiola, Nora Diéguez-Martínez, Xianming Deng, Mingfeng Hao, Walter W. Massefski et al. · 2018 · ACS Chemical Biology
  6. Monitoring and deciphering protein degradation pathways inside cells
    Danette L. Daniels, Kristin M. Riching, Marjeta Urh · 2018 · Drug Discovery Today Technologies
  7. Targeting BET bromodomain proteins in cancer: The example of lymphomas
    Filippo Spriano, Anastasios Stathis, Francesco Bertoni · 2020 · Pharmacology & Therapeutics
  8. Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
    Esin Orhan, Carolina Velázquez, Imène Tabet, Claude Sardet, Charles G. Theillet · 2021 · Cancers
  9. Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates
    Hai‐Tsang Huang, Ryan J. Lumpkin, Ryan W. Tsai, Shuyao Su, Xu Zhao, Yuan Xiong, James Chen, Nada Mageed, Katherine A. Donovan, Eric S. Fischer et al. · 2024 · Nature Chemical Biology
  10. Targeting MYC Proteins for Tumor Therapy
    Elmar Wolf, Martin Eilers · 2019 · Annual Review of Cancer Biology
  11. Discovery of a Potent and Selective Degrader for USP7
    Yuan Pei, Jingfeng Fu, Yunkai Shi, Mengmeng Zhang, Guanghao Luo, Xiaomin Luo, Ning Song, Tian Mi, Yaxi Yang, Jia Xuan Li et al. · 2022 · Angewandte Chemie International Edition
  12. Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke
    Kelly M. DeMars, Changjun Yang, Eduardo Candelario‐Jalil · 2019 · Neurochemistry International
  13. The genomic and spatial mobility of extrachromosomal DNA and its implications for cancer therapy
    Eric van Leen, Lotte Brückner, Anton George Henssen · 2022 · Nature Genetics
  14. BRD4-targeting PROTAC as a unique tool to study biomolecular condensates
    Yi Shi, Yuan Liao, Qianlong Liu, Zhihao Ni, Zhenzhen Zhang, Minglei Shi, Pilong Li, Haitao Li, Yu Rao · 2023 · Cell Discovery
  15. Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype
    Gang Xue, Jianing Xie, Matthias Hinterndorfer, Marko Cigler, Lara Dötsch, Hana Imrichová, Philipp Lampe, Xiu‐Fen Cheng, Soheila Rezaei Adariani, Georg E. Winter et al. · 2023 · Nature Communications
  16. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer
    Aileen Patricia Szczepanski, Zibo Zhao, Tori Sosnowski, Young Ah Goo, Elizabeth T. Bartom, Lu Wang · 2020 · Genome Medicine
  17. Fast-acting chemical tools to delineate causality in transcriptional control
    Martin G. Jaeger, Georg E. Winter · 2021 · Molecular Cell
  18. Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen–Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design
    Eron, Scott J., Huang, Hongwei, Agafonov, Roman V., Fitzgerald, Mark E., Patel, Joe, Michael, Ryan E., Lee, Tobie D., Hart, Ashley A., Shaulsky, Jodi, Nasveschuk, Christopher G. et al. · 2021 · ACS Chemical Biology
  19. Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
    Ye Chen, Liang Xu, Anand Mayakonda, Mo-Li Huang, Deepika Kanojia, Tuan Zea Tan, Pushkar Dakle, Ruby Yu‐Tong Lin, Xinyu Ke, JONATHAN W. SAID et al. · 2019 · Nature Communications
  20. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
    Vivian Y.L. Chua, Marlana M. Orloff, Jessica L.F. Teh, Takahito Sugase, Connie Liao, Timothy J. Purwin, Bao Lam, Mizue Terai, Grazia Ambrosini, Richard D. Carvajal et al. · 2019 · EMBO Molecular Medicine
  21. BRD4: An emerging prospective therapeutic target in glioma
    Hua Yang, Li Wei, Yang Xun, Anping Yang, Hua You · 2021 · Molecular Therapy — Oncolytics
  22. Machine Learning Modeling of Protein-Intrinsic Features Predicts Tractability of Targeted Protein Degradation
    Zhang, Wubing, Roy Burman, Shourya S., Chen, Jiaye, Donovan, Katherine A., Cao, Yang, Shu, Chelsea, Zhang, Boning, Zeng, Zexian, Gu, Shengqing, Zhang, Yi et al. · 2022 · Genomics, Proteomics & Bioinformatics
  23. Targeting cyclin-dependent kinase 9 in cancer therapy
    Yili Shen, Yanmao Wang, Yaxin Zhang, Shen-jie Ma, Lehe Yang, Chengguang Zhao, Xiaoying Huang · 2021 · Acta Pharmacologica Sinica
  24. BRD4: a general regulator of transcription elongation
    Elisabeth Altendorfer, Yelizaveta Mochalova, Andreas Mayer · 2022 · Transcription
  25. BET Inhibition Induces HEXIM1- and RAD51-Dependent Conflicts between Transcription and Replication
    Akhil Bowry, Ann Liza Piberger, Patricia Rojas, Marco Saponaro, Eva Petermann · 2018 · Cell Reports
  26. GeneWalk identifies relevant gene functions for a biological context using network representation learning
    Robert Ietswaart, Benjamin M. Gyori, John A. Bachman, Peter Karl Sorger, L. Stirling Churchman · 2021 · Genome biology
  27. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
    Norihito Shibata, Kenichiro Shimokawa, Katsunori Nagai, Nobumichi Ohoka, Takayuki Hattori, Naoki Miyamoto, Osamu Ujikawa, Tomoya Sameshima, Hiroshi Nara, Nobuo Cho et al. · 2018 · Scientific Reports
  28. The Bromodomain Protein 4 Contributes to the Regulation of Alternative Splicing
    Sheetal Uppal, Anne Gégonne, Qingrong Chen, Petria S. Thompson, Dan Cheng, Jie Mu, Daoud M. Meerzaman, Hari Sharan Misra, Dinah S. Singer · 2019 · Cell Reports
  29. Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure
    Luisa Mori, Susana T. Valente · 2020 · Viruses
  30. Chromatin Looping Shapes KLF5-Dependent Transcriptional Programs in Human Epithelial Cancers
    Yanli Liu, Bingqian Guo, Estrella Aguilera-Jimenez, Vivian S. Chu, Jin Rong Zhou, Zhong Wu, Joshua M. Francis, Xiaojun Yang, Peter S. Choi, Swneke Donovan Bailey et al. · 2020 · Cancer Research
  31. Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy
    M. Catarina Silva, Ghata Nandi, Katherine A. Donovan, Quan Cai, Bethany C. Berry, Radosław P. Nowak, Eric S. Fischer, Nathanael S. Gray, Fleur M. Ferguson, Stephen J. Haggarty · 2022 · Frontiers in Cellular Neuroscience
  32. A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles
    Hafiz Akbar Ali, Yalan Li, Akram Hafiz Muhammad Bilal, Tingting Qin, Ziqiao Yuan, Wen He Zhao · 2022 · Frontiers in Pharmacology
  33. Three amphioxus reference genomes reveal gene and chromosome evolution of chordates
    Zhen J. Huang, Luohao Xu, Cheng Cai, Yitao Zhou, Jing Liu, Zaoxu Xu, Zexian Zhu, Wen Kang, Wan Cen, Surui Pei et al. · 2023 · Proceedings of the National Academy of Sciences
  34. Acute perturbation strategies in interrogating RNA polymerase II elongation factor function in gene expression
    Bin Zheng, Yuki Aoi, Avani P. Shah, Marta Iwanaszko, Siddhartha Das, Emily Jane Rendleman, Didi Zha, Nabiha Haleema Khan, Edwin R. Smith, Ali Shilatifard · 2021 · Genes & Development
  35. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4
    Nasiha S. Ahmed, Jovylyn Gatchalian, Josephine Ho, Mannix J. Burns, Nasun Hah, Zong Wei, Michael Downes, Ronald M. Evans, Diana C. Hargreaves · 2021 · Proceedings of the National Academy of Sciences
  36. HIV-1 Proviral Transcription and Latency in the New Era
    Ashutosh Shukla, Nora-Guadalupe P. Ramirez, Iván D’Orso · 2020 · Viruses
  37. Biophysical and Computational Approaches to Study Ternary Complexes: A ‘Cooperative Relationship’ to Rationalize Targeted Protein Degradation
    Jake A. Ward, Carles Perez‐Lopez, Cristina Mayor‐Ruiz · 2023 · ChemBioChem
  38. The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
    Saki Ichikawa, N. Connor Payne, Wenqing Xu, Chia‐Fu Chang, Nandini Vallavoju, Spencer Frome, Hope A. Flaxman, Ralph Mazitschek, Christina M. Woo · 2024 · Cell chemical biology
  39. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2
    Kristin M. Riching, Marie K. Schwinn, James D. Vasta, Matthew B. Robers, Thomas Machleidt, Marjeta Urh, Danette L. Daniels · 2020 · SLAS DISCOVERY
  40. Oncogenic dysregulation of pre‐mRNA processing by protein kinases: challenges and therapeutic opportunities
    Chiara Naro, Pamela Bielli, Claudio Sette · 2021 · FEBS Journal
  41. Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead
    Radosław P. Nowak, Leah Ragosta, Fidel Huerta, Hu Liu, Scott B. Ficarro, Justin T. Cruite, Rebecca J. Metivier, Katherine A. Donovan, Jarrod A. Marto, Eric S. Fischer et al. · 2023 · RSC Chemical Biology
  42. Conserved DNA sequence features underlie pervasive RNA polymerase pausing
    Martyna Gajos, Olga Jasnovidova, Alena van Bömmel, Susanne Freier, Martin Vingron, Andreas Mayer · 2021 · Nucleic Acids Research
  43. Enhancer dysfunction in leukemia
    Anand S. Bhagwat, Bin Lu, Christopher R. Vakoc · 2018 · Blood
  44. Targeted protein degradation mechanisms
    Yi Zhang, Christine Loh, Jesse Chen, Nello Mainolfi · 2019 · Drug Discovery Today Technologies
  45. A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader
    Payne, N. Connor, Maksoud, Semer, Tannous, Bakhos A., Mazitschek, Ralph · 2022 · Cell Chemical Biology
  46. BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression
    Qiong Wu, Fangfang Liu, Mengmeng Ge, Kyle Vaughn Laster, Lixiao Wei, Ruijuan Du, Ming Jiang, Jing Zhang, Yafei Zhi, Guoguo Jin et al. · 2021 · Oncogene
  47. The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage
    Xingfei Zhu, Wei Liu, Xiangcheng Tang, Yu-Lin Chen, Xiangyu Ge, Qin Ke, Xingmiao Liang, Yuwen Gan, Yingfeng Zheng, Ming Zou et al. · 2023 · Journal of Neuroinflammation
  48. Small molecules as tools to study the chemical epigenetics of lysine acetylation
    Matthias Schiedel, Stuart J. Conway · 2018 · Current Opinion in Chemical Biology
  49. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
    Diana Reyes-Garau, Marcelo Lima Ribeiro, Gaël Roué · 2019 · Cancers
  50. Cohesin couples transcriptional bursting probabilities of inducible enhancers and promoters
    Irene Robles-Rebollo, Sergi Cuartero, Adrià Cañellas-Socias, Sarah Wells, Mohammad Mahdi Karimi, Elisabetta Mereu, Alexandra G. Chivu, Holger Heyn, Chad Whilding, Dirk Dormann et al. · 2022 · Nature Communications
  51. Degraders in epigenetic therapy: PROTACs and beyond
    Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, Gao-Zhi Liu, Huimin Liu, Shaopeng Wang, Liang Shen, Ning Wang, Piet A. Herdewijn, Yi‐Chao Zheng et al. · 2024 · Theranostics
  52. dbCoRC: a database of core transcriptional regulatory circuitries modeled by H3K27ac ChIP-seq signals
    Moli Huang, Ye Chen, Manqiu Yang, An‐Yuan Guo, Ying Xu, Liang Xu, Harold Phillip Koeffler · 2017 · Nucleic Acids Research
  53. Benefit of Apabetalone on Plasma Proteins in Renal Disease
    Sylwia Wasiak, Laura M. Tsujikawa, Christopher Halliday, Stephanie C. Stotz, Dean Gilham, Ravi Jahagirdar, Kamyar Kalantar‐Zadeh, Richard A. Robson, Michael Sweeney, Jan O. Johansson et al. · 2017 · Kidney International Reports
  54. Positive Regulation of Transcription by Human ZMYND8 through Its Association with P-TEFb Complex
    Koushik Ghosh, Ming Tang, Nidhi Kumari, Arijit Nandy, Subham Basu, Dheerendra Pratap Mall, Kunal Rai, Debabrata Biswas · 2018 · Cell Reports
  55. Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
    Raoul Tibes, James M. Bogenberger · 2019 · Frontiers in Oncology
  56. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
    Natalie S. Scholes, Cristina Mayor‐Ruiz, Georg E. Winter · 2021 · Cell chemical biology
  57. Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
    Shane D. Falcinelli, Jackson J. Peterson, Anne-Marie W. Turner, David Irlbeck, Jenna Read, Samuel L.M. Raines, Katherine S. James, Cameron Sutton, Anthony Sanchez, Ann Emery et al. · 2022 · Journal of Clinical Investigation
  58. Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition
    Timothy R. Bishop, Chitra Subramanian, Eric M. Bilotta, Leopold Garnar-Wortzel, Anissa R. Ramos, Yuxiang Zhang, Joshua N. Asiaban, Christopher J. Ott, Charles O. Rock, Michael A. Erb · 2023 · Nature Chemical Biology
  59. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors
    Heli Fan, Zhili Zhou, Dehao Yu, Jing Fang Sun, Luo Wang, Yuanyuan Jia, Junyu Tian, Wenyi Mi, Huabing Sun · 2023 · Bioorganic Chemistry
  60. Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera
    Adam G. Bond, Miquel Muñoz i Ordoño, Celia M. Bisbach, Conner Craigon, Nikolai Makukhin, Elizabeth A. Caine, Manjula Nagala, Marjeta Urh, Georg E. Winter, Kristin M. Riching et al. · 2024 · Journal of the American Chemical Society
  61. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism
    Jie Li, Phillip M. Galbo, Weida Gong, Aaron J. Storey, Yi‐Hsuan Tsai, Xufen Yu, Jeong Hyun Ahn, Yiran Guo, Samuel G. Mackintosh, Ricky D. Edmondson et al. · 2021 · Nature Communications
  62. RNase H1, the Gold Standard for R-Loop Detection
    Susana M. Cerritelli, Kiran Sakhuja, Robert J. Crouch · 2022 · Methods in molecular biology
  63. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
    Xuelian Liu, Anjin Wang, Yuying Shi, Mengyuan Dai, Miao Liu, Hongbing Cai · 2023 · Molecules
  64. Targeting bromodomain-containing proteins: research advances of drug discovery
    Zhaoping Pan, Yuxi Zhao, Xiaoyun Wang, Xin Xie, Mingxia Liu, Kaiyao Zhang, Lian Wang, Ding Bai, Leonard J. Foster, Rui Shu et al. · 2023 · Molecular Biomedicine
  65. ByeTAC: Bypassing E-Ligase-Targeting Chimeras for Direct Proteasome Degradation
    Cody A. Loy, Eslam M.H. Ali, Laurence J. Seabrook, Timothy J. Harris, Kate A. Kragness, Lauren Veronica Albrecht, Darci Jones Trader · 2025 · Journal of Medicinal Chemistry
  66. Evolutionary conserved NSL complex/BRD4 axis controls transcription activation via histone acetylation
    Aline Gaub, Bilal N. Sheikh, Maria Felicia Basilicata, Marie Vincent, Mathilde Nizon, Cindy Colson, Matthew Bird, James E. Bradner, Julien Thévenon, Michael Boutros et al. · 2020 · Nature Communications
  67. Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
    Jing Liu, Yunhua Peng, Wenyi Wei · 2021 · Frontiers in Cell and Developmental Biology
  68. The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells
    Noortje van Gils, Tània Martiáñez, Eline Vermue, Arjo P. Rutten, Fedor Denkers, Tiem van der Deure, Gert Jan Ossenkoppele, Francis Joseph Giles, Linda Smit · 2021 · HemaSphere
  69. Fragment Linker Prediction Using the Deep Encoder-Decoder Network for PROTACs Drug Design
    Chien‐Ting Kao, Chieh‐Te Lin, Cheng-Li Chou, Chu‐Chung Lin · 2023 · Journal of Chemical Information and Modeling
  70. Pooled multicolour tagging for visualizing subcellular protein dynamics
    Andreas Reicher, Jiří Reiniš, Maria Ciobanu, Pavel Růžička, Monika Malik, Marton I. Siklos, Viktoriia Kartysh, Tatjana Tomek, Anna Koren, André F. Rendeiro et al. · 2024 · Nature Cell Biology
  71. BRD4 and MYC—clarifying regulatory specificity
    Arianna Sabò, Bruno B. Amati · 2018 · Science
  72. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
    Daniel J. Coleman, Lina Gao, Jacob A. Schwartzman, James E. Korkola, David Sampson, Daniel S. Derrick, Joshua A. Urrutia, Ariel I. Balter, Julja Burchard, Carly J. King et al. · 2019 · Scientific Reports
  73. Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models
    Youya Nakazawa, Masayuki Miyano, Shuntaro Tsukamoto, Hiroyuki Kogai, Akihiko Yamamoto, Kentaro Iso, Satoshi Inoue, Yoshinobu Yamane, Yuki Yabe, Hirotatsu Umihara et al. · 2024 · Nature Communications
  74. Acute Pharmacologic Degradation of a Stable Antigen Enhances Its Direct Presentation on MHC Class I Molecules
    Sarah C. Moser, Jane S.A. Voerman, Dennis L. Buckley, Georg E. Winter, Christopher Schliehe · 2018 · Frontiers in Immunology
  75. Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma
    Günther H.S. Richter, Tim Hensel, Oxana Schmidt, Vadim Saratov, Kristina von Heyking, Fiona AG Becker-Dettling, Carolin Prexler, Hsi-Yu Yen, Katja Steiger, Simone Fulda et al. · 2020 · Cancers
  76. Chemically induced degradation of epigenetic targets
    Md Kabir, Xufen Yu, H. Ümit Kanıskan, Jian Jun Jin · 2023 · Chemical Society Reviews
  77. Chemical Epigenetics: The Impact of Chemical and Chemical Biology Techniques on Bromodomain Target Validation
    Matthias Schiedel, Mustafa Moroglu, David M. H. Ascough, Anna E. R. Chamberlain, Jos J. A. G. Kamps, Angelina R. Sekirnik, Stuart J. Conway · 2019 · Angewandte Chemie International Edition
  78. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL
    Sujan Piya, Ya‐Ling Yang, Seemana Bhattacharya, Priyanka Sharma, Huaxian Ma, Hong Hua Mu, Hua He, Vivian R. Ruvolo, Natalia Baran, Richard Eric Davis et al. · 2022 · Leukemia
  79. Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer
    Steven Kregel, Rohit Malik, Irfan Ahmed Asangani, Kari Wilder-Romans, Thekkelnaycke M. Rajendiran, Lanbo Xiao, Josh N. Vo, Tanu Soni, Marcin P. Cieslik, Ester Fernández‐Salas et al. · 2019 · Clinical Cancer Research
  80. Identification and characterization of cancer vulnerabilities via targeted protein degradation
    Mayor-Ruiz, Cristina, Winter, Georg E. · 2019 · Drug Discovery Today: Technologies
  81. Protein degraders - from thalidomide to new PROTACs
    Takumi Ito · 2023 · The Journal of Biochemistry
  82. IRF2 is a master regulator of human keratinocyte stem cell fate
    Nicolas Mercado, Gabi Schutzius, Christian Kolter, David Estoppey, Sebastian Bergling, Guglielmo Roma, Caroline Gubser Keller, Florian Nigsch, Adrian Salathe, Rémi Terranova et al. · 2019 · Nature Communications
  83. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
    Marcelo Lima Ribeiro, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano, Gaël Roué · 2019 · Frontiers in Genetics
  84. Targeted Protein Degradation: Clinical Advances in the Field of Oncology
    Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, Iris Z. Uras · 2022 · International Journal of Molecular Sciences
  85. A modular CRISPR screen identifies individual and combination pathways contributing to HIV-1 latency
    Emily Hsieh, Derek H. Janssens, Patrick J. Paddison, Edward P. Browne, Steven Henikoff, Molly OhAinle, Michael Emerman · 2023 · PLoS Pathogens
  86. PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution
    Yaw Asante, Katharina Benischke, Issra Osman, Quy Ai Ngo, Jakob Wurth, Dominik Laubscher, Hyunmin Kim, Bhavatharini Udhayakumar, Md Imdadul H. Khan, Diana H. Chin et al. · 2023 · Nature Communications
  87. Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
    Shenglan Liu, Wei Dai, Bei Jin, Feng Jiang, Hao Huang, Wen Hou, Jin‐Xia Lan, Yanli Jin, Weijie Peng, Jingxuan Pan · 2024 · Molecular Cancer
  88. Methylarginine targeting chimeras for lysosomal degradation of intracellular proteins
    Laurence J. Seabrook, Carolina N. Franco, Cody A. Loy, Jaida M. Osman, Callie Fredlender, Jan Zimak, Melissa Campos, Steven T. Nguyen, Richard L. Watson, Samantha R. Levine et al. · 2024 · Nature Chemical Biology
  89. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature
    Ian Landry, Vikram Sumbly, Mallorie Vest · 2022 · Cureus
  90. SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues
    Trever R. Carter, Natalia Milosevich, Lucas Dada, James B. Shaum, Karl Barry Sharpless, Seiya Kitamura, Michael A. Erb · 2024 · Bioorganic & Medicinal Chemistry
  91. Expanding the ligand spaces for E3 ligases for the design of protein degraders
    Rahman Shah Zaib Saleem, Martin P. Schwalm, Stefan Knapp · 2024 · Bioorganic & Medicinal Chemistry
  92. mRNA export factors store nascent transcripts within nuclear speckles as an adaptive response to transient global inhibition of transcription
    Tobias D. Williams, Ewa Malgorzata Michalak, Kirstyn T. Carey, Enid Y.N. Lam, Ashley Anderson, Esther Griesbach, Yih-Chih Chan, Panagiotis Papasaikas, Vicky W. T. Tan, Linh Ngo et al. · 2025 · Molecular Cell
  93. The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells
    Gernot Wolf, Conner Craigon, Shao Thing Teoh, Patrick Essletzbichler, Svenja Onstein, Diane M. Cassidy, Esther C. H. Uijttewaal, Vojtech Dvorak, Yuting Cao, Ariel Bensimon et al. · 2025 · Cell chemical biology
  94. The phenylalanine-and-glycine repeats of NUP98 oncofusions form condensates that selectively partition transcriptional coactivators
    Jeong Hyun Ahn, Yiran Guo, Heankel Lyons, Samuel G. Mackintosh, Benjamin K. Lau, Ricky D. Edmondson, Stephanie D. Byrum, Aaron J. Storey, Alan J. Tackett, Ling Cai et al. · 2025 · Molecular Cell
  95. High-throughput ligand diversification to discover chemical inducers of proximity
    James B. Shaum, Miquel Muñoz i Ordoño, Erica A. Steen, Daniela Vanessa Wenge, Hakyung Cheong, Jordan Janowski, Moritz Hunkeler, Eric M. Bilotta, Zoe J. Rutter, Paige A. Barta et al. · 2026 · Nature Chemical Biology
  96. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma
    Warren C. Fiskus, Christopher Peter Mill, Dimuthu Nuwan Perera, Christine E. Birdwell, Qing Deng, Haopeng Yang, Bernardo H Lara, Nitin Jain, Jan A. Burger, Alessandra Ferrajoli et al. · 2021 · Leukemia
  97. Extrachromosomal circular DNA in colorectal cancer: biogenesis, function and potential as therapeutic target
    Yinnan Chen, Quanpeng Qiu, Junjun She, Jun Qing Yu · 2023 · Oncogene
  98. Multivalent Role of Human TFIID in Recruiting Elongation Components at the Promoter-Proximal Region for Transcriptional Control
    Dipika Yadav, Koushik Ghosh, Subham Basu, Robert G. Roeder, Debabrata Biswas · 2019 · Cell Reports
  99. Intrinsic signaling pathways modulate targeted protein degradation
    Mori Yuki, Yoshino Akizuki, Rikuto Honda, Miyu Takao, Ayaka Tsuchimoto, Sota Hashimoto, Hiroaki Iio, Masakazu Kato, Ai Kaiho-Soma, Yasushi Saeki et al. · 2024 · Nature Communications
  100. Rational Design of PROTAC Linkers Featuring Ferrocene as a Molecular Hinge to Enable Dynamic Conformational Changes
    Alessandra Salerno, Lianne H. E. Wieske, Claudia J. Diehl, Alessio Ciulli · 2025 · Journal of the American Chemical Society